How is microRNA testing different from traditional protein biomarker tests like PSA or CA-125?

Traditional protein biomarkers like PSA (prostate-specific antigen) or CA-125 (ovarian cancer) have several well-documented limitations: they are organ-specific (PSA only for prostate), they have high false-positive rates (PSA is elevated in benign prostatic hyperplasia and infection), and they are often not elevated until disease is advanced. MicroRNA biomarkers differ fundamentally: they are early molecular signals that precede protein changes, they can be detected across multiple cancer types from a single test, and the Yenos HL normalization approach enables a binary YES/NO result rather than a probabilistic score. OncuraKit is specifically designed for people who have received inconclusive or borderline results from traditional tests like PSA and colonoscopy.